Merck & Co., Inc. (MRK) Balance Sheet

The balance sheet is expanding rapidly, with total assets growing from $105.8B to $129.8B over the same period, but equity has remained relatively flat, indicating that growth is increasingly debt-funded. This trend aligns with the prior income statement analysis showing a surge in R&D spending and negative operating income in 2026Q1, suggesting that the company is borrowing to finance its pipeline investments. Investors should monitor whether this leverage increase is temporary or signals a structural shift in capital structure.

The debt-to-assets ratio has risen from 0.32 in 2024Q1 to 0.42 in 2026Q2, indicating that over 40% of assets are now financed by debt. While this is still manageable relative to peers like Amgen (D/E 6.31) and BMY (D/E 2.55), the rapid pace of debt accumulation suggests a strategic pivot toward leveraging the balance sheet to bridge the Keytruda patent cliff. The company's high gross margin of 72% provides a buffer, but the absence of updated guidance in the latest earnings report leaves the sustainability of this leverage uncertain.

The asset mix remains heavily weighted toward intangibles, with goodwill alone representing 16.6% of total assets, a level that warrants monitoring for potential impairment if pipeline setbacks occur. The increase in PPE from $23.0B to $25.7B over the period aligns with the reported expansion of Gardasil manufacturing capacity, suggesting management is betting on future vaccine demand. However, with revenue growth only 1.2% TTM, this capacity build appears to be a forward-looking investment that may not pay off if demand disappoints.

The decline in retained earnings, despite cumulative operating cash flow of $47.3B over the last ten quarters, suggests that the company is distributing more to shareholders than it is retaining, likely through dividends and buybacks. This is consistent with the prior cash flow analysis showing consistent $2.0B quarterly dividends and periodic buybacks. However, with net income turning negative in 2026Q1, the equity base is being eroded, which could limit financial flexibility if the R&D surge does not translate into revenue growth.

The current ratio remains above 1, suggesting adequate short-term solvency, but the sharp decline in cash from $14.6B to $6.8B in just two quarters is notable. This cash drawdown likely funded debt repayments or operational needs, given the negative operating income in 2026Q1. With a cash balance of $6.8B against total debt of $53.9B, the company's buffer against shocks is thinning, though its strong operating cash flow generation (cumulative $47.3B over ten quarters) provides some comfort.